Stocks Stage Comeback as Tariff Jitters Subside
The NASDAQ Composite and S&P 500 moved higher on Tuesday thanks to a strong gain in Palantir, as Wall Street tries to find stable footing following the latest developments on the global trade front.Shares in the Dow Jones Industrials edged up 13.03 points to 44,434.97.The much-broader index pointed higher 32.44 points to 6,027.01The NASDAQ flew 225.79 points, or 1.2%, to 19,617.73. Palantir shares popped 26% on fourth-quarter results that beat analyst expectations and had hit a fresh record high during the session.The Chinese government slapped tariffs of up to 15% on U.S. imports of coal and liquefied natural gas and 10% higher duties on crude oil, farm equipment and selected cars, effective Feb. 10.The move comes after the U.S. agreed to pause more aggressive levies on Canada and Mexico. Canadian Prime Minister Justin Trudeau announced in a post on social media site X on Monday evening that Trump agreed to halt the implementation of tariffs against Canada for at least 30 days. Earlier on Monday, Mexican President Claudia Sheinbaum announced that duties on Mexico imports to the U.S. would also be halted for a month.Prices for the 10-year Treasury slid, raising yields to 4.55% from Tuesday’s 4.54%. Treasury prices and yields move in opposite directions.Oil prices decreased 25 cents to $72.91 U.S. a barrel. Prices for gold gained $16.30 an ounce to $2,873.40 U.S.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


